Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Feb 13, 2025)

Reports
Leadership Changes
Filing Date
Filed February 13, 2025
Period End
February 11, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed February 13, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported in this Form 8-K, filed February 13, 2025, that director Connie L.

Matsui notified the Company on February 11, 2025, of her intention not to stand for reelection at the Company's 2025 annual meeting of stockholders. The filing is limited to this board change under Item 5.02(b), and it contains no financial results, guidance, or other operational or strategic disclosures. The Company and its Board of Directors thanked Ms. Matsui for her nearly 18 years of service, describing her counsel as sage advice.

The filing states that her decision was not the result of any disagreement with the Company, any matter related to its operations, policies, practices or strategy, its management, or the Board. For investors, the disclosure is a routine board transition with no stated financial impact. It signals a board seat that will open after the 2025 annual meeting, and the filing does not name a successor or describe any related compensation arrangements.

Key Highlights

  1. Director Connie L. Matsui notified the Company on February 11, 2025, that she will not stand for reelection at the 2025 annual meeting of stockholders.
  2. Ms. Matsui served on the Board for nearly 18 years, which the Company acknowledged with thanks.
  3. The filing states her departure was not due to any disagreement with the Company, its operations, policies, practices, strategy, management, or Board.
  4. The disclosure is made under Item 5.02(b) and covers only a board membership change.
  5. The filing does not name a successor director or disclose any new compensatory arrangements.
  6. No financial results, guidance, or other financial figures are reported in this filing.

Frequently Asked Questions

  1. Why is Connie L. Matsui leaving Halozyme's board?

    The filing states that she notified the Company on February 11, 2025, of her intention not to stand for reelection at the 2025 annual meeting. It also states that her decision was not the result of any disagreement with the Company, its operations, policies, practices or strategy, its management, or the Board.

  2. How long did Ms. Matsui serve on the Board?

    The Company's management and Board thanked her for nearly 18 years of providing sage advice to the Company.

  3. When will Ms. Matsui's board service end?

    The filing indicates she will not stand for reelection at the Company's 2025 annual meeting of stockholders, so her service would end at that meeting.

  4. Does this filing include any financial or operational news?

    No. The filing covers only Ms. Matsui's notice of non-reelection and contains no financial results, guidance, or other operational disclosures.

  5. Has Halozyme named a replacement for Ms. Matsui?

    The filing does not name a successor or describe any board appointment.